Geron Scraps Phase 3 Myelofibrosis Trial After DMC Says Survival Endpoint Unlikely
GERN is trading near its 52-week low of $1.04 (11% above the low).
Summary
Geron is discontinuing the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis after the independent Data Monitoring Committee advised the trial was unlikely to hit its primary overall survival endpoint. The trial had enrolled 327 patients randomized 2:1 against best available therapy. No new safety signals emerged, so the approved RYTELO label in lower-risk MDS is not directly threatened. The blow is to the pipeline: imetelstat's expansion into higher-risk myelofibrosis was the main growth story beyond the current commercial franchise, and that path is now closed. Management is pivoting the message to growing RYTELO demand in the U.S. and expanding access outside the U.S., backed by the $326.9M cash position reported with Q2 results. This lands just as the interim analysis was expected in H2 2026, so the negative read is arriving on schedule rather than as a surprise delay.
At the time of this announcement, GERN was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $738.8M. The 52-week trading range was $1.04 to $2.01. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.